


Claims

1. Use of the compounds of the following formula (I):



wherein X represents OH, (C_{1-5})alkoxy, NH_2 , $NH-C_{1-5}$ -alkyl, $N(C_{1-5}$ alkyl) $_2$;


R_1 is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a (C_{1-5}) alkoxy group, a (C_{1-5}) alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;

R_2 is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu and Asn;

R_3 and R_4 independently represent H, OH, (C_{1-C_5})alkyl, or (C_{1-5})alkoxy, provided that R_3 and R_4 are not both OH or (C_{1-5})alkoxy;

R_5 represents H, OH, (C_{1-5}) alkyl or (C_{1-5})alkoxy;

and wherein R_0 represents a group of the formula



wherein Y represents -CO-, -CH₂CO-, -CH₂CH₂CO-, -CH₂CH₂CH₂CO-, -CH=CH-CO or -OCH₂CO-, and wherein Z represents a halogen atom, a trifluormethyl group, (C₁₋₄) alkoxy group, (C₁₋₄) alkyl group; or wherein two neighbouring substituents may form a (C₁₋₃) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5; or pharmaceutically acceptable salts thereof;

for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic, traumatic or toxic origin.

2. The use according to claim 1, wherein R₁ is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. The use according to claim 2, wherein R₁ is a residue derived from Phe which may optionally be substituted by a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom.

4. The use according to any of the preceding claims, wherein X is (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂.

5. The use according to any of the preceding claims, wherein R₂ is a residue derived from the amino acid Gly or Ile.

6. The use according to any of the preceding claims, wherein R₀ is a cinnamoyl moiety.

7. The use according to any of the preceding claims, wherein the compound of formula (I) is cinnamoyl-glycyl-L-phenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-

L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.